AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
Part of Cancer, Lungs & breathing clinical trials.
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer that has spread to other parts of your body (stage IV).
- Your tumor has an EGFR mutation, specifically the L858R change or an exon 19 deletion.
- You are 18 years old or older and your overall health is relatively good (KPS score 70 or higher).
- Brain metastases were found when you were first diagnosed with lung cancer.
- You have received or are currently receiving a third-generation targeted therapy pill (like osimertinib/Tagrisso) with or without brain radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
This trial tests whether adding focused radiation therapy to the spots of cancer that remain after your first treatment (an EGFR pill plus chemo) can help control advanced lung cancer better. It is for people whose cancer has an EGFR mutation and who have only a few residual spots, with the goal of delaying progression and improving outcomes.
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
This trial tests whether adding nitroglycerin (a medicine that widens blood vessels) to standard whole-brain radiation helps improve treatment for lung cancer that has spread to the brain. It is for people with a specific gene change (EGFR mutation) in their cancer.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.